SKYRIZI 150 MG / 1 ML — DIN 02519283
RISANKIZUMAB : 150 MG / 1 ML · ABBVIE CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is SKYRIZI?
SKYRIZI 150 MG / 1 ML contains RISANKIZUMAB : 150 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02519283, held by ABBVIE CORPORATION, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 01-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SKYRIZI used for?
Moderate to severe plaque psoriasis; active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Rizankizumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Rizankizumab — 7 DINs, of which 5 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 7 | 5 | SKYRIZI | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG / 1 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 150mg/mL pre-filled pen or syringe; 180mg/1.2mL and 360mg/2.4mL cartridges with on-body injector; 90mg/mL pre-filled syringes (pack of 4); 600mg/10mL vials. |
| Storage | Store refrigerated at 2°C to 8°C. Keep in original carton to protect from light. Do not freeze. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Rizankizumab |
|---|---|
| ATC code | L04AC18 |
| AHFS class | 84:06.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02519283 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2519283 |
| Brand name | SKYRIZI |
| Generic / active ingredient | RISANKIZUMAB : 150 MG / 1 ML |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | L04AC18 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L04AC |
| Current status | MARKETED |
| Status date | 01-Jun-2022 |
| Original market date | 2022-06-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Psoriasis/PsA: 150mg SC at Week 0, 4, then every 12 weeks. Crohn’s: 600mg IV at Week 0, 4, 8, then 360mg SC at Week 12 and every 8 weeks. UC: 1200mg IV at Week 0, 4, 8, then 180mg or 360mg SC every 8 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to risankizumab or to any ingredient in the formulation or component of the container.
Warnings and precautions
May increase risk of infections; do not use in patients with active TB or clinically important active infections. Serious hypersensitivity reactions (anaphylaxis) may occur. Avoid live vaccines.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SKYRIZI | 150 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | 02519291 |
| SKYRIZI | 360 MG / 2.4 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | 02532093 |
| SKYRIZI | 60 MG | SOLUTION | ABBVIE CORPORATION | MARKETED | 02532107 |
| SKYRIZI | 180 MG / 1.2 ML | SOLUTION | ABBVIE CORPORATION | MARKETED | 02552507 |
| SKYRIZI | 75 MG / 0.83 ML | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | 02487454 |
| SKYRIZI | 90 MG / 1 ML | SOLUTION | ABBVIE CORPORATION | APPROVED | 02546922 |
2 · Same class — other molecules in ATC L04AC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ustekinumab | FINLIUS · FINLIUS I.V. · JAMTEKI · JAMTEKI I.V. · +10 more | 25 | 24 | Yes |
| Tocilizumab | ACTEMRA · TYENNE | 10 | 10 | Yes |
| Mirikizumab | OMVOH | 7 | 7 | Yes |
| Rizankizumab | SKYRIZI | 7 | 5 | Yes |
| Secukinumab | COSENTYX | 6 | 5 | Yes |
| Guselkumab | TREMFYA · TREMFYA I.V. · TREMFYA ONE-PRESS | 5 | 4 | Yes |
| Bimekizumab | BIMZELX | 4 | 4 | Yes |
| Sarilumab | KEVZARA | 4 | 3 | Yes |
| Siltuximab | SYLVANT | 2 | 2 | Yes |
| Spesolimab | SPEVIGO | 2 | 2 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L04A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L04AX | Azathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more | 191 | 124 |
| L04AB | Adalimumab · Certolizumab Pegol · Etanercept · Golimumab · Infliximab | 71 | 55 |
| L04AA | Abatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more | 73 | 42 |
| L04AD | Ciclosporin · Tacrolimus | 49 | 30 |
| L04AK | Leflunomide · Teriflunomide | 44 | 25 |
| L04AH | Everolimus · Sirolimus | 36 | 23 |
| L04AF | Baricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib | 23 | 19 |
| L04AG | Alemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more | 20 | 15 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.